You are here

HemoShear Therapeutics, LLC

Company Information
Address
501 Locust Ave Ste 301
Charlottesville, VA 22902-4870
United States



Information

UEI: EYEHGTVJK567

# of Employees: 25


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No




Success Stories

  1. SBIR-STTR-Success: Making Cells Feel at Home in the Lab Leads to Better Drugs for Rare Diseases

    Human cells can tell the difference between a petri dish and a human body. This can make developing treatments in the laboratory very difficult because treatment that works in a lab sample could fail when given to a patient.HemoShear Therapeutics, in Charlottesville, Virginia, solves this problem...

Award Charts




Award Listing

  1. Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism

    Amount: $1,171,782.00

    Fast Track SBIRIdentification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism defectsABSTRACT There are very few reliable methods to study and unders ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Validation of targets for therapeutic intervention in NASH

    Amount: $1,862,227.00

    Direct to Phase II SBIRValidation of targets for therapeutic intervention in NASHABSTRACT Non alcoholic steatohepatitisNASHis part of the progressive disease spectrum of non alcoholic fatty liver dise ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  3. Validation of a human in vitro system of hepatic steatohepatitis

    Amount: $1,210,475.00

    Phase II SBIR Validation of a human in vitro system of hepatic steatohepatitis ABSTRACT Non alcoholic steatohepatitis NASH is part of the progressive disease spectrum of non alcoholic fatty liver ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  4. Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism

    Amount: $1,215,005.00

    Fast Track SBIR Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism defects ABSTRACT There are very few reliable methods to study and unde ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  5. IGF OT IGF SBIR PHASE II TOPIC TITLE VALIDATION OF THE HEMOSHEAR TUMOR MICROENVIRONMENT SYSTEM FOR DRUG DISCOVERY AND DEVELOPMENT

    Amount: $1,985,884.00

    Not Available

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  6. Development of a DIVI platform for issue resolution in pre-clinical drug development.

    Amount: $1,199,998.00

    DESCRIPTION provided by applicant Drug induced vascular injury DIVI is a common phenomenon in pre clinical animal studies and is typically characterized by hemorrhage vascular endothelial and sm ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  7. Development of an iPSC-derived human hepatocyte platform for drug development.

    Amount: $1,689,857.00

    DESCRIPTION provided by applicant Human inducible pluripotent stem cells iPSCs proliferate readily and can be terminally differentiated into hepatocytes which potentially makes them an attractiv ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  8. Development of an in vitro system of human hepatic steatosis.

    Amount: $255,128.00

    DESCRIPTION provided by applicant Non alcoholic fatty liver disease NAFLD is a rapidly emerging public health crisis affecting up to of Type diabetics and of obese individuals Glucose ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  9. Development of a human physiological multi-cellular liver platform for drug-induced liver injury and disease.

    Amount: $463,475.00

    DESCRIPTION provided by applicant Liver cell based systems are widely used to study drug metabolism toxicity and liver disease However the poor correlation between in vitro data and clinical out ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  10. Development of an iPSC-derived human vascular system for drug discovery and devel

    Amount: $249,013.00

    DESCRIPTION (provided by applicant): R43 SBIR: Development of an iPSC-derived human vascular system for drug development. ABSTRACT Human inducible pluripotent stem cells (iPSCs) can be differentiated ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government